Abalone Bio
Abalone Bio is a preclinical-stage biotech company dedicated to developing antibody drugs for challenging targets such as GPCRs, ion channels, and membrane proteins. They leverage engineered biology and machine learning to create target-activating antibodies, unlocking new therapeutic possibilities for diseases with unmet medical needs. Their proprietary platform, FAST, enables high-throughput functional antibody discovery and AI-guided design, focusing on targets that are difficult to drug with traditional methods. The company's mission is to create highly specific, active antibodies that can modulate biological targets effectively, aiming to treat more patients with fewer side effects.
Industries
Nr. of Employees
small (1-50)
Abalone Bio
Patents
Products
Preclinical CB2-targeting antibody agonists (preclinical candidates)
CB2-specific antibody agonists identified via cell-based functional selection that reduce macrophage activation in vitro, attenuate fibrotic marker expression in ex vivo liver slices, reduce fibrosis in a therapeutic mouse model, and alleviate behavioral hypersensitivity in a chemotherapy-induced peripheral neuropathy mouse model.
Internal discovery pipeline for metabolic, inflammation and cancer indications
Preclinical discovery-stage antibody programs focused on metabolic disease (including obesity), inflammation, and cancer, leveraging functional antibody selection and ML-guided design to access targets that benefit from activating antibodies.
Preclinical CB2-targeting antibody agonists (preclinical candidates)
CB2-specific antibody agonists identified via cell-based functional selection that reduce macrophage activation in vitro, attenuate fibrotic marker expression in ex vivo liver slices, reduce fibrosis in a therapeutic mouse model, and alleviate behavioral hypersensitivity in a chemotherapy-induced peripheral neuropathy mouse model.
Internal discovery pipeline for metabolic, inflammation and cancer indications
Preclinical discovery-stage antibody programs focused on metabolic disease (including obesity), inflammation, and cancer, leveraging functional antibody selection and ML-guided design to access targets that benefit from activating antibodies.
Services
Collaborative discovery campaigns using large-scale functional screening and ML to identify antibodies that activate or modulate challenging membrane protein targets.
Co-development of selected antibody assets from discovery through preclinical optimization in partnership with development/commercialization partners.
Collaborative discovery campaigns using large-scale functional screening and ML to identify antibodies that activate or modulate challenging membrane protein targets.
Co-development of selected antibody assets from discovery through preclinical optimization in partnership with development/commercialization partners.
Expertise Areas
- Functional antibody discovery for membrane proteins (GPCRs)
- High-throughput assay and selection development
- Antibody library design and engineering
- Sequence-to-function data analytics and ML-guided protein design
Key Technologies
- Yeast cell-based functional screening
- Engineered expression of human GPCRs in yeast
- Next-generation sequencing (NGS) for library readouts
- Protein large language models (LLMs) and generative design
News & Updates
A news event highlighting Abalone Bio's use of AI to discover weight loss therapeutics.
A news article about Abalone Bio's platform for discovering functional antibodies for challenging targets.
A media piece on Abalone Bio's efforts to develop better weight-loss drugs.
An article discussing Abalone Bio's platform for discovering GPCR-targeting antibodies that modulate activity.
An interview detailing Abalone Bio's mission to develop antibodies that activate challenging drug targets.
A news piece on Abalone Bio's platform for discovering and creating active antibody drugs.
A news event highlighting Abalone Bio's use of AI to discover weight loss therapeutics.
A news article about Abalone Bio's platform for discovering functional antibodies for challenging targets.
A media piece on Abalone Bio's efforts to develop better weight-loss drugs.
An article discussing Abalone Bio's platform for discovering GPCR-targeting antibodies that modulate activity.
An interview detailing Abalone Bio's mission to develop antibodies that activate challenging drug targets.
A news piece on Abalone Bio's platform for discovering and creating active antibody drugs.